Telix Pharmaceuticals (NASDAQ:TLX) Receives “Outperform” Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a $22.00 target price on the stock.

A number of other equities research analysts also recently issued reports on TLX. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen downgraded Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, January 19th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Tuesday. Finally, Citigroup increased their price objective on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.13.

Telix Pharmaceuticals Stock Up 5.9%

Shares of Telix Pharmaceuticals stock opened at $9.63 on Tuesday. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $20.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The company’s 50-day moving average price is $7.76 and its 200-day moving average price is $8.71.

Telix Pharmaceuticals (NASDAQ:TLX) last announced its quarterly earnings results on Friday, February 20th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The firm had revenue of $206.72 million for the quarter, compared to analysts’ expectations of $421.50 million. As a group, research analysts expect that Telix Pharmaceuticals will post 0.24 earnings per share for the current year.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Portland Investment Counsel Inc. purchased a new stake in Telix Pharmaceuticals in the third quarter valued at approximately $1,225,000. Lazard Asset Management LLC purchased a new stake in Telix Pharmaceuticals in the third quarter valued at approximately $1,097,000. Russell Investments Group Ltd. purchased a new stake in Telix Pharmaceuticals during the second quarter valued at about $975,000. Private Advisor Group LLC raised its position in Telix Pharmaceuticals by 67.3% during the third quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after purchasing an additional 16,945 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in Telix Pharmaceuticals during the fourth quarter valued at about $276,000.

More Telix Pharmaceuticals News

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Company Q1 2026 update reports strong revenue growth, continued commercial traction and advancement of its therapeutics pipeline; guidance was reaffirmed, which supports the stock’s rally. Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
• Positive Sentiment: Wedbush reaffirmed an Outperform rating with a $22 price target, signaling strong analyst confidence in Telix’s growth trajectory and providing material upside versus the current share level. This call is being cited as a key driver of today’s buying. Why Is Telix Pharma Stock Soaring?
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating with a $20 target, another supportive broker view that reinforces upside expectations among investors. HC Wainwright Buy Rating
• Positive Sentiment: Press and analyst commentary highlight further upside scenarios — some coverage projects additional gains (one piece argues shares could still rise ~40%), which can attract momentum buyers. Why rebounding Telix shares could still rise 40%
• Neutral Sentiment: Analyst consensus remains cautiously positive (reported as a “Moderate Buy”), indicating broad but measured support rather than unanimous conviction. Consensus Rating: Moderate Buy
• Negative Sentiment: Remains a risk: recent quarterly results showed an EPS miss and revenue below some street expectations earlier this year, which investors should weigh against the upbeat guidance and analyst notes. Recent EPS and revenue miss (background)

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.